US 7,517,949 B2
	Livin-derived peptides, compositions and uses thereof
Dina Ben-Yehuda, Mevasseret Zion (Israel); Yaqoub Ashhab, Hebron (Israel); and Boaz Nachmias, Ramat-Gan (Israel)
Assigned to Hadasit Medical Research Services & Development Ltd., Jerusalem (Israel)
Appl. No. 10/559,639 PCT Filed May 31, 2004, PCT No. PCT/IL2004/000461 § 371(c)(1), (2), (4) Date Jul. 24, 2006, PCT Pub. No. WO2004/106371, PCT Pub. Date Dec. 09, 2004.
Claims priority of application No. 156263 (IL), filed on Jun. 02, 2003.
Prior Publication US 2007/0244040 A1, Oct. 18, 2007
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); C12P 21/06 (2006.01); C12N 15/00 (2006.01); C07H 21/04 (2006.01)

U.S. Cl. 530—300  [435/69.1; 435/320.1; 536/23.1; 536/23.5]

10 Claims

1. An isolated or synthetic livin-derived peptide selected from one of p30-Livin α and p28-Livin β, wherein said p30-Livin α peptide comprises the sequence as defined in SEQ ID NO:1 having pro-apoptotic activity, and wherein said p28-Livin β peptide comprises the sequence as defined in SEQ ID NO:2 having pro-apoptotic activity.